Related Experiment Video

Updated: Jul 7, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Targeting the cGAS-STING Pathway Inhibits Peripheral T-cell Lymphoma Progression and Enhances the Chemotherapeutic

Xueying Lu1,2,3, Shunan Wang1,2,3, Xin Hua4

  • 1Lymphoma Center, Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|December 25, 2023
PubMed

Insights

Targeting the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway suppresses peripheral T-cell lymphoma (PTCL) growth and enhances chemotherapy efficacy. Cdc2-like kinase 1 (CLK1) inhibition improves sensitivity to cGAS inhibitors in PTCL treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Peripheral T-cell lymphoma (PTCL) is a diverse group of T-cell cancers with poor treatment outcomes.
  • The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is implicated in tumor promotion.
  • Novel therapeutic strategies are needed for PTCL, particularly for relapsed/refractory cases.

Purpose of the Study:

  • To investigate the role and mechanisms of the cGAS-STING pathway in PTCL progression.
  • To evaluate the therapeutic potential of targeting the cGAS-STING pathway in PTCL.
  • To identify potential biomarkers for predicting response to cGAS-STING inhibitors.

Main Methods:

  • Single-cell RNA sequencing to analyze cGAS-STING pathway expression in PTCL.
  • Functional assays to assess the impact of cGAS inhibition on tumor growth and DNA repair.
  • Single-cell dynamic transcriptomic analysis to elucidate underlying mechanisms.
  • In vitro studies to evaluate the combination of cGAS inhibitors with chemotherapy and CLK1 inhibition.

Main Results:

  • The cGAS-STING pathway is highly expressed and associated with PTCL proliferation.
  • Inhibition of cGAS suppresses PTCL tumor growth and impairs DNA damage repair.
  • Cdc2-like kinase 1 (CLK1) is crucial for residual tumor cell survival post-cGAS inhibition.
  • CLK1 suppression enhances PTCL sensitivity to cGAS inhibitors, linked to reduced proliferation.
  • cGAS inhibitors synergize with chemotherapy by targeting DNA damage-induced pathway activation.

Conclusions:

  • The cGAS-STING pathway is oncogenic in PTCL and targeting it offers a therapeutic strategy.
  • Combined targeting of cGAS and CLK1 may overcome resistance and improve PTCL treatment outcomes.
  • CLK1 could serve as a predictive biomarker for cGAS inhibitor sensitivity in PTCL.
  • These findings support the development of novel therapeutic approaches for PTCL, especially relapsed/refractory disease.
Keywords:
CLK1DNA damage repairscGAS-STING pathwaysperipheral T-cell lymphomasingle-cell RNA sequencing

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

772
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K